Vivistim in the News

Do you have a media inquiry?

Connect with Us
  • March 31, 2025

    A Revolutionary Treatment for Stroke: How a Vagus Nerve Stimulation Implant is Giving Patients Renewed Hope

    See More
  • March 30, 2025

    AdventHealth Orlando Pioneers Implants for Stroke Survivors

    See More
  • PRESS RELEASE March 12, 2025

    MicroTransponder Secures $65 Million to Enhance Vivistim Adoption for Chronic Stroke Recovery

    See More
  • March 12, 2025

    MicroTransponder secures US$65 Million Financing Round to Boost Adoption of Vivistim Stroke Therapy

    See More
  • March 07, 2025

    100 great neuro and spine programs – 2024

    See More
  • March 03, 2025

    Powers Health First in Indiana to Use Vivistim Paired VNS System to Help Stroke Survivors

    See More
  • February 27, 2025

    “Game Changing” Procedure for Stroke Patients | SMH HealthCasts: Rehab Series

    See More
  • February 27, 2025

    Vivistim Therapy: Bridging the Gap from “Not Yet” to “Approved” | No Plateau Podcast

    See More
  • February 17, 2025

    Ischaemic stroke outcomes with Vivistim paired VNS therapy highlighted at ISC 2025

    See More
  • February 13, 2025

    Perseverance Leads to New Beginning

    See More
  • February 12, 2025

    Rehabilitation with Vivistim

    See More
  • February 11, 2025

    Transforming lives of stroke survivors: AdventHealth, Orlando Neurosurgery first in nation to perform 50 Vivistim implant cases

    See More
  • February 07, 2025

    MicroTransponder Vivistim nerve stim tech delivers positive stroke outcomes

    See More
  • PRESS RELEASE February 05, 2025

    Vivistim Paired VNS Therapy Outcomes & Success at Comprehensive Stroke Centers Highlighted at ISC 2025

    See More
  • February 02, 2025

    Perseverance Leads to New Beginnings

    See More

Awards

©2023 TIME USA LLC. All rights reserved. Used under license.

Get Started Today

Complete the qualification questionnaire
and one of our therapy specialists will call you to discuss whether Vivistim is right for you.